Focus: Gilead Sciences is a $27.1B revenue public biotech leader specializing in HIV/AIDS, hepatitis, oncology, and infectious disease with 18,000 employees. The company maintains market dominance through peak-stage antivirals and is actively expanding into cancer via protein degraders and antibody-drug conjugates.
Profile data last refreshed 5h ago · AI intelligence enriched 2w ago
Hot — 213 jobs added in 30d
Net +76 (213 new, 137 removed). Aggressive expansion phase.
4 recent layoff filings (12 mo) — 107 affected
Source: state DOL filings via Big Local News
Gilead offers stability and scale for infectious disease and oncology careers, but revenue concentration and early-stage pipeline require comfort with execution risk and evolving public health scrutiny.
Franchise anchor delivering 46% of total revenue with 10+ year exclusivity runway, but represents significant concentration risk.
Help build intelligence for Gilead Sciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Gilead Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Second-largest product facing competitive erosion and generics, with LOE within 8 years.
HIV backbone product approaching LOE in 7 years; part of maturing HIV portfolio.
Dual-indication product with near-term patent cliff.
7 discontinued, 19 duplicate formulations not shown
+10 more products with revenue data
Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines - MedCity News
Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines MedCity News
Commentary: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people - Los Angeles Times
Commentary: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people Los Angeles Times
Gilead's Stock Price is Expected to Rise to $160,Gilead’s $5 Billion Tubulis Deal Could Reshape the Cancer Drug Market of America - TradingKey
Gilead's Stock Price is Expected to Rise to $160,Gilead’s $5 Billion Tubulis Deal Could Reshape the Cancer Drug Market of America TradingKey
Gilead Sciences Acquires Tubulis for $3 Billion - National Today
Gilead Sciences Acquires Tubulis for $3 Billion National Today
Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis - BioPharma Dive
Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis BioPharma Dive
Gilead Sciences Price Target Raised by Royal Bank Of Canada - National Today
Gilead Sciences Price Target Raised by Royal Bank Of Canada National Today
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Effect of Biomarker Confirmed Unhealthy Alcohol Use on Viral Suppression Among Adolescents and Young Adults With HIV in East Africa.
Requirements for patient-reported outcomes and data analytics in health technology assessment in England, France and Germany, and the need for methods harmonization across European markets: a qualitative interview study.
Source: state DOL filings, aggregated via Big Local News
No active FDA warnings or WARN filings detected; reputational risk from access/pricing criticism (LA Times, Apr 2026) may drive regulatory and political scrutiny but not imminent operational disruption.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo